The Food and Drug Administration has had a busy summer, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.
Although life in the United States came to a screeching halt several months ago at the onset of COVID-19, the Food and Drug Administration (FDA) ensured that the agency would continue to approve cancer drugs and not be affected by the pandemic.
In fact, the FDA has continued to approve numerous drugs well into the summer. In case you missed it, CURE® compiled a list of five recent FDA approvals.
First CAR T-Cell Therapy, Tecartus, for Relapsed or Refractory Mantle Cell Lymphoma
The FDA’s approval of Tecartus for adults with relapsed or refractory mantle cell lymphoma (MCL) is based on data that showed the CAR T-cell therapy induced a response in 87% of patients. READ MORE.
Monjuvi-Revlimid Combination for Relapsed/Refractory DLBCL
The FDA’s approval of Monjuvi-Revlimid is based on results that demonstrated that the combination induced a response in 55% of patients with relapsed/refractory DLBLC. READ MORE.
Tecentriq in Combination with Cotellic and Zelboraf for Patients with Advanced Skin Cancer
The trial the agency based its decision on showed that adding Tecentriq to Cotellic and Zelboraf demonstrated a 4.5-month improvement of median progression-free survival, compared with placebo plus Cotellic and Zelboraf (15.1 months versus 10.6 months). READ MORE.
Bavencio as Frontline Maintenance Therapy in Advanced Bladder Cancer
Compared with best supportive care alone, frontline maintenance treatment with Bavencio resulted in a 31% reduction in the risk for death in the overall study population. READ MORE.
Oral Combination of Inquovi and Cedazuridine for Patients with Myelodysplastic Syndromes
The FDA approved the oral combination for adults with several subtypes of MDS. READ MORE.